Merit Medical Systems (MMSI) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $339.8 million, up 7.8% year-over-year, with constant currency revenue up 7.9% and organic constant currency revenue up 5.7%.

• GAAP net income for Q3 was $28.4 million ($0.48 per share), up from $25.8 million ($0.44 per share) in Q3 2023; non-GAAP net income was $51.2 million ($0.86 per share), up 21.1%.

• Free cash flow for Q3 was $38 million, totaling $120 million for the first nine months, up 116% year-over-year.

• Completed acquisition of EndoGastric Solutions assets in July 2024 and announced agreement to acquire Cook Medical's lead management portfolio for $210 million, expected to close in Q4 2024.

• Announced positive pivotal trial results for the WrapsodyTM device for dialysis patients and advanced regulatory filings.

Financial highlights

• GAAP gross margin for Q3 2024 was 46.4% (up from 45.1%); non-GAAP gross margin was 50.9% (up from 49.8%).

• GAAP operating margin was 11.0%; non-GAAP operating margin was 19.2%, up 175 basis points year-over-year.

• Operating expenses rose 6%, with SG&A up 5% and R&D up 8%.

• Cash and equivalents at quarter-end were $523.1 million; total debt $770.5 million; net leverage ratio 2.08x.

• Operating cash flow for the first nine months was $152.1 million; capital expenditures were $31.7 million.

Outlook and guidance

• FY2024 GAAP net revenue guidance: $1.344–$1.352 billion, up 6.9%–7.6% year-over-year; constant currency growth 7.4%–8.1%.

• Cardiovascular segment expected to grow 5%–6.2%; endoscopy segment 49%–52%.

• Non-GAAP EPS guidance raised to $3.33–$3.38, up 17%–19% year-over-year.

• Free cash flow guidance increased to at least $150 million for 2024.

• Guidance includes projected impacts from the Cook Medical acquisition, expected to close November 1, 2024.